U.S. Markets open in 2 hrs 58 mins
  • S&P Futures

    4,225.00
    +15.25 (+0.36%)
     
  • Dow Futures

    33,406.00
    +102.00 (+0.31%)
     
  • Nasdaq Futures

    13,369.25
    +58.00 (+0.44%)
     
  • Russell 2000 Futures

    1,985.10
    +8.80 (+0.45%)
     
  • Crude Oil

    94.29
    -0.05 (-0.05%)
     
  • Gold

    1,802.50
    -4.70 (-0.26%)
     
  • Silver

    20.24
    -0.11 (-0.56%)
     
  • EUR/USD

    1.0295
    -0.0030 (-0.2883%)
     
  • 10-Yr Bond

    2.8880
    0.0000 (0.00%)
     
  • Vix

    20.12
    +0.38 (+1.93%)
     
  • GBP/USD

    1.2131
    -0.0072 (-0.5871%)
     
  • USD/JPY

    133.5400
    +0.5410 (+0.4068%)
     
  • BTC-USD

    23,882.05
    -573.93 (-2.35%)
     
  • CMC Crypto 200

    567.81
    -6.93 (-1.21%)
     
  • FTSE 100

    7,493.90
    +27.99 (+0.37%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

Investors in Champions Oncology (NASDAQ:CSBR) have made a impressive return of 197% over the past five years

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far more than 100% on a really good stock. For instance, the price of Champions Oncology, Inc. (NASDAQ:CSBR) stock is up an impressive 197% over the last five years.

With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.

View our latest analysis for Champions Oncology

We don't think that Champions Oncology's modest trailing twelve month profit has the market's full attention at the moment. We think revenue is probably a better guide. Generally speaking, we'd consider a stock like this alongside loss-making companies, simply because the quantum of the profit is so low. It would be hard to believe in a more profitable future without growing revenues.

In the last 5 years Champions Oncology saw its revenue grow at 23% per year. Even measured against other revenue-focussed companies, that's a good result. Meanwhile, its share price performance certainly reflects the strong growth, given the share price grew at 24% per year, compound, during the period. This suggests the market has well and truly recognized the progress the business has made. Champions Oncology seems like a high growth stock - so growth investors might want to add it to their watchlist.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

We know that Champions Oncology has improved its bottom line over the last three years, but what does the future have in store? If you are thinking of buying or selling Champions Oncology stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

While the broader market lost about 16% in the twelve months, Champions Oncology shareholders did even worse, losing 23%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. On the bright side, long term shareholders have made money, with a gain of 24% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. Shareholders might want to examine this detailed historical graph of past earnings, revenue and cash flow.

But note: Champions Oncology may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.